| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/26/2002 | US6361760 Aerosol composition comprising tricyclic compound or pharmaceutically acceptable salt thereof, liquefied hydrofluoroalkane and medium-chain fatty acid triglyceride |
| 03/26/2002 | US6361758 Cosolvent formulations |
| 03/26/2002 | US6360743 System for dispensing pharmaceutical active compounds |
| 03/26/2002 | CA2333024C Method for the treatment of insomnia |
| 03/26/2002 | CA2266599C Method and composition for rewetting contact lenses and relieving eye dryness |
| 03/26/2002 | CA2234249C Therapeutic diet for dogs with lymphoma |
| 03/26/2002 | CA2230682C Sugar-free dragee-like products |
| 03/26/2002 | CA2176670C 15-deoxyspergualin analogs, their method of preparation and their use in therapeutics |
| 03/26/2002 | CA2115029C Cyclic urethanes useful as antiarrhythmic and antifibrillatory agents |
| 03/26/2002 | CA2097740C Product and process for treating bovine mastitis and bovine metritis |
| 03/26/2002 | CA2097176C New pharmaceutical formulations containing a pharmacologically active ionizable substance as well as process for the preparation thereof |
| 03/26/2002 | CA2094703C Substituted piperazines as central nervous system agents |
| 03/26/2002 | CA2089954C 4-amino-2-ureidopyrimidine-5-carboxamides, a process for the preparation thereof, pharmaceuticals containing these compounds, and the use thereof |
| 03/26/2002 | CA2072513C Lozenge or chewable tablet |
| 03/26/2002 | CA2063030C Substituted n-phenylpiperidines and drugs therefrom |
| 03/26/2002 | CA2054409C Fat mixture for infant and adult nutrition |
| 03/26/2002 | CA2051260C Anti-oxidant system based on a basic amino acid associated with at least one tocopherol or one of its derivatives and at least one non-thiolated polypeptide, and compositions containing such an anti-oxidant system |
| 03/26/2002 | CA2034096C Controlled absorption naproxen formulation for once-daily administration |
| 03/26/2002 | CA2032498C Novel 8-substituted-2-aminotetralines |
| 03/26/2002 | CA2027665C Agent for preventing and treating opacity of lens |
| 03/26/2002 | CA2005925C Compositions and new pharmaceutical products for the regeneration of leucocytes and their use in the treatment of the immunodeficiency syndrome |
| 03/22/2002 | CA2357578A1 Use of prenylated flavones |
| 03/22/2002 | CA2357306A1 Fused ring system containing indole as m4 selective aza-anthracene muscarinic receptor antagonists |
| 03/22/2002 | CA2356829A1 Method for treating asthma using pregabalin |
| 03/21/2002 | WO2002023190A2 Methods and products related to low molecular weight heparin |
| 03/21/2002 | WO2002022819A2 Calcium binding proteins |
| 03/21/2002 | WO2002022807A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 03/21/2002 | WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses |
| 03/21/2002 | WO2002022682A1 Interferon-alpha induced gene |
| 03/21/2002 | WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides |
| 03/21/2002 | WO2002022658A2 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers |
| 03/21/2002 | WO2002022655A1 Glutathione conjugates with distamycin derivatives having antitumoral activity |
| 03/21/2002 | WO2002022647A1 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids |
| 03/21/2002 | WO2002022645A2 Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity |
| 03/21/2002 | WO2002022642A1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy |
| 03/21/2002 | WO2002022635A1 Antisense modulation of clusterin expression |
| 03/21/2002 | WO2002022630A1 Purine derivatives |
| 03/21/2002 | WO2002022621A2 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 03/21/2002 | WO2002022620A2 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists |
| 03/21/2002 | WO2002022615A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022614A1 Quinolizine derivatives |
| 03/21/2002 | WO2002022613A1 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
| 03/21/2002 | WO2002022612A1 Thiazolidine derivatives and its use as antifungal agent |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022610A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | WO2002022609A1 Process for producing paroxetine salt containing substantially no organic solvent |
| 03/21/2002 | WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022602A2 Triazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors |
| 03/21/2002 | WO2002022600A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022599A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022598A1 Quinolinone derivatives as tyrosine kinase inhibitors |
| 03/21/2002 | WO2002022597A1 N-phenyl-2-pyrimidine-amine derivatives |
| 03/21/2002 | WO2002022595A1 N-substituted benzothiophenesulfonamide derivatives |
| 03/21/2002 | WO2002022592A2 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | WO2002022588A1 Novel pyrimidine derivative and novel pyridine derivative |
| 03/21/2002 | WO2002022585A1 Tetrahydroquinoline compounds |
| 03/21/2002 | WO2002022584A1 Thrombin inhibitors |
| 03/21/2002 | WO2002022581A1 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 03/21/2002 | WO2002022580A1 Antibacterials mutilins |
| 03/21/2002 | WO2002022577A2 Hydroxamate derivatives useful as deacetylase inhibitors |
| 03/21/2002 | WO2002022575A1 Amidine inhibitors of serine proteases |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022559A2 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022557A2 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022204A2 Transdermal electrotransport device and method for manufacturing same |
| 03/21/2002 | WO2002022175A2 Method and composition for treating tumors by selective induction of apoptosis |
| 03/21/2002 | WO2002022171A2 Pharmaceutical composition having specific water activity |
| 03/21/2002 | WO2002022163A1 Remedies for ischemic diseases |
| 03/21/2002 | WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | WO2002022146A2 Components of canola for treating hyperlipidemia |
| 03/21/2002 | WO2002022145A2 Components of canola for the treatment of cancer |
| 03/21/2002 | WO2002022144A1 The uses of chinese herb piper laetispicum c. dc and its extract for the preparation of pharmaceutical composition |
| 03/21/2002 | WO2002022141A2 Xenon as medicament |
| 03/21/2002 | WO2002022140A1 Homeostasis-maintaining agents |
| 03/21/2002 | WO2002022139A1 Intraarticular agent for the treatment of osteoarthritis |
| 03/21/2002 | WO2002022138A1 Antibacterial agents and methods of identification |
| 03/21/2002 | WO2002022137A1 β-LACTAM ANALOGS AND USES THEREFOR |
| 03/21/2002 | WO2002022136A1 Diphosphonate solutions |
| 03/21/2002 | WO2002022135A1 Creatine ester pronutrient compounds and formulations |
| 03/21/2002 | WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | WO2002022133A1 Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| 03/21/2002 | WO2002022132A2 Novel topical oestroprogestational compositions with systemic effect |
| 03/21/2002 | WO2002022131A1 Eye drops |
| 03/21/2002 | WO2002022130A2 Means for regulating immune defences |
| 03/21/2002 | WO2002022129A1 A method of analgesia |
| 03/21/2002 | WO2002022128A1 A method of local anesthesia and analgesia |
| 03/21/2002 | WO2002022127A1 Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
| 03/21/2002 | WO2002022126A1 Gatifloxacin pentahydrate |
| 03/21/2002 | WO2002022125A1 Methods for delaying recurrence of herpes virus symptoms |